ECM1 has previously been implicated in breast cancer metastasis and plays a critical role in its progression by activating cholesterol biosynthesis, inducing NOTCH-mediated endothelial feedback and regulating actin cytoskeletal architecture through alterations in S100A4 and Rho A, suggesting its utility as an adjuvant therapeutic agent (28–33). Here, ECM1 is linked to breast cancer.